Evidence map›Paper›PMID 41595254›Full record

ReviewCancers2026

First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review.

Ilma Khan, Priyal Agarwal, Nassar El Assaad, Ravin Ratan, Elise F Nassif Haddad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ilma KhanDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 78712, USA.
Priyal AgarwalDivision of Hematology and Medical Oncology, Medical University of South Carolina, Charleston, SC 29425, USA.
Nassar El AssaadDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 78712, USA.ORCID 0009-0007-0114-7441
Ravin RatanDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 78712, USA.
Elise F Nassif HaddadDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 78712, USA.ORCID 0000-0003-3794-6759

Funding

Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMSP50CA272170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Scott Michael Schuetze · 2022 to 2026
$13.3M
NCI NIH HHS K12 CA088084NCI NIH HHS P50 CA272170
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

doxorubicinfirst-linegemcitabineleiomyosarcomatoxicity

Identifiers

PMID41595254
PMCPMC12838646

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.